These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38023561)

  • 1. A National HIV Provider Survey of Antiretroviral Therapy Preferences for Management of Treatment-Naive and Experienced Individuals With Drug Resistance.
    Krishnan S; Lippincott CK; Bjerrum S; Martinez Rivera MB; Shah M
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad541. PubMed ID: 38023561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 antiretroviral resistance: scientific principles and clinical applications.
    Tang MW; Shafer RW
    Drugs; 2012 Jun; 72(9):e1-25. PubMed ID: 22686620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.
    Tashima KT; Mollan KR; Na L; Gandhi RT; Klingman KL; Fichtenbaum CJ; Andrade A; Johnson VA; Eron JJ; Smeaton L; Haubrich RH
    HIV Clin Trials; 2015 Aug; 16(4):147-56. PubMed ID: 26212575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study.
    Parbie PK; Abana CZ; Kushitor D; Asigbee TW; Ntim NAA; Addo-Tetebo G; Ansong MRD; Ofori SB; Mizutani T; Runtuwene LR; Nishizawa M; Ishikawa K; Kiyono H; Ampofo WK; Matano T; Bonney EY; Kikuchi T
    Front Microbiol; 2022; 13():973771. PubMed ID: 36090108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
    Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
    PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.
    Günthard HF; Saag MS; Benson CA; del Rio C; Eron JJ; Gallant JE; Hoy JF; Mugavero MJ; Sax PE; Thompson MA; Gandhi RT; Landovitz RJ; Smith DM; Jacobsen DM; Volberding PA
    JAMA; 2016 Jul; 316(2):191-210. PubMed ID: 27404187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Validation of HIV-ASSIST, an Online, Educational, Clinical Decision Support Tool to Guide Patient-Centered ARV Regimen Selection.
    Maddali MV; Mehtani NJ; Converse C; Kapoor S; Pham P; Li JZ; Shah M
    J Acquir Immune Defic Syndr; 2019 Oct; 82(2):188-194. PubMed ID: 31513553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
    Karade S; Sen S; Sashindran VK
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
    Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Musengimana G; Tuyishime E; Kiromera A; Malamba SS; Mulindabigwi A; Habimana MR; Baribwira C; Ribakare M; Habimana SD; DeVos J; Mwesigwa RCN; Kayirangwa E; Semuhore JM; Rwibasira GN; Suthar AB; Remera E
    Antivir Ther; 2022 Jun; 27(3):13596535221102690. PubMed ID: 35593031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.
    Orkin C; Llibre JM; Gallien S; Antinori A; Behrens G; Carr A
    HIV Med; 2018 Jan; 19(1):18-32. PubMed ID: 28737291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.
    Girón-Callejas A; García-Morales C; Mendizabal-Burastero R; Román M; Tapia-Trejo D; Pérez-García M; Quiroz-Morales VS; Juárez SI; Ravasi G; Vargas C; Gutiérrez R; Romero L; Solórzano A; Sajquim E; Northbrook S; Ávila-Ríos S; Reyes-Terán G
    J Int AIDS Soc; 2019 Dec; 22(12):e25429. PubMed ID: 31860167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
    Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
    BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
    Kagan RM; Dunn KJ; Snell GP; Nettles RE; Kaufman HW
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):698-709. PubMed ID: 31169022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.
    Günthard HF; Aberg JA; Eron JJ; Hoy JF; Telenti A; Benson CA; Burger DM; Cahn P; Gallant JE; Glesby MJ; Reiss P; Saag MS; Thomas DL; Jacobsen DM; Volberding PA;
    JAMA; 2014 Jul 23-30; 312(4):410-25. PubMed ID: 25038359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV drug resistance profile in South Africa: Findings and implications from the 2017 national HIV household survey.
    Moyo S; Hunt G; Zuma K; Zungu M; Marinda E; Mabaso M; Kana V; Kalimashe M; Ledwaba J; Naidoo I; Takatshana S; Matjokotja T; Dietrich C; Raizes E; Diallo K; Kindra G; Mugore L; Rehle T
    PLoS One; 2020; 15(11):e0241071. PubMed ID: 33147285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
    de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
    Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.